You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK):2款在研抗癌新藥的最新臨牀前研究結果入選2022年美國癌症研究協會(AACR)年會
格隆匯 03-27 19:18

格隆匯3月27日丨 歌禮制藥-B(01672.HK)董事會欣然宣佈公司2款在研抗癌新藥,口服PD-L1小分子抑制劑ASC61和脂肪酸合成酶(FASN)抑制劑ASC60的最新臨牀前研究結果入選2022年美國癌症研究協會(AACR)年會(“2022年AACR年會”)。摘要內容現已在AACR官網公佈。

公吿顯示,AACR年會是全球歷史最悠久、規模最大的腫瘤研究學術會議之一。會議關注高質量腫瘤研究及創新的各個方面,是全球腫瘤研究的焦點,彙集腫瘤領域的最前沿的研究成果。本屆AACR年會將於美國中部時間2022年4月8日至13日在美國路易斯安那州新奧爾良舉行。

入選2022年AACR年會的壁報展示的摘要信息如下:

(1) ASC61

摘要標題:口服PD-L1抑制劑ASC61在兩種腫瘤小鼠模型中的體內療效評估

報吿形式:壁報展示

摘要編號:5529

會議類別:免疫

會議主題:免疫治療臨牀前研究

報吿時間:美國中部時間2022年4月8日下午12:00-1:00

報吿人╱作者:吳勁梓、何菡萏,歌禮生物科技(杭州)有限公司

ASC61是一款強效、高選擇性的口服PD-L1小分子抑制劑,通過誘導PD-L1二聚體的形成和內吞,從而阻斷PD-1/PD-L1的相互作用。臨牀前研究顯示,在同基因腫瘤小鼠模型及人源化腫瘤小鼠模型中,ASC61均顯示顯著抑制腫瘤生長的作用,其抑瘤效果優於或與阿特珠單抗(Atezolizumab,已獲美國食品藥品監督管理局(FDA)批准的PD-L1治療性單克隆抗體)相當,且耐受性良好。ASC61在晚期實體瘤患者中的美國I期臨牀試驗申請已獲FDA批准,第一例患者預計於2022年第二季度入組。

(2) ASC60

摘要標題:口服脂肪酸合成酶抑制劑ASC60在兩種腫瘤小鼠模型中的療效驗證

報吿形式:壁報展示

摘要編號:5466

會議類別:實驗和分子治療

會議主題:小分子治療藥物

報吿時間:美國中部時間2022年4月8日下午12:00-1:00

報吿人╱作者:吳勁梓、何菡萏,歌禮生物科技(杭州)有限公司

ASC60是一款強效、選擇性、安全的口服小分子脂肪酸合成酶(FASN)抑制劑,通過阻斷脂肪酸從頭合成(DNL),從而破壞腫瘤細胞中的代謝和腫瘤相關信號轉導。臨牀前小鼠腫瘤模型研究顯示,ASC60可有效抑制腫瘤生長並加強mPD-1抗體的抑瘤效果。歌禮已向中國國家藥品監督管理局藥品審評中心遞交ASC60治療晚期實體瘤的I期臨牀試驗申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account